Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy

Catheterization and Cardiovascular Interventions

Volumn 57, Issue 3, 2002, Pages 279-283

  Allaqaband, Suhail ^a,b   Tumuluri, Ramagopal ^a   Malik, Ahmed M ^a   Gupta, Anjan ^a   Volkert, Paul ^a   Shalev, Yoseph ^a   Bajwa, Tanvir K ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b AURORA SINAI MEDICAL CENTER   (United States)

Author keywords

Fenoldopam; N acetylcysteine; Prevention; Radiocontrast induced nephropathy

Indexed keywords

ACETYLCYSTEINE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOLDOPAM; FENOLDOPAM MESILATE; NONIONIC CONTRAST MEDIUM; SODIUM CHLORIDE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR PROCEDURES; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HEART CATHETERIZATION; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; INTERVENTIONAL RADIOLOGY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; OSMOLALITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REHYDRATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACETYLCYSTEINE; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; FEMALE; FENOLDOPAM; FREE RADICAL SCAVENGERS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RISK FACTORS; SODIUM CHLORIDE; STROKE VOLUME; TREATMENT OUTCOME;

EID: 0036843034     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10323     Document Type: Article

References (20)

1. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older: A prospective study. Arch Intern Med 1990;150:1237-1242.
2. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: Results of PRINCE study. J Am Coll Cardiol 1999;33:403-411.
3. Solomon R, Werner C, Mann D, et al. Effect of saline, mannitol, and furosemide on acute decrease in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-1420.
4. Hou SH, Bushinsky DA, Wish JB, et al. Hospital-acquired renal insufficiency: A prospective study. Am J Med 1983;74:243-248.
5. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: A cohort analysis. JAMA 1996;275:1489- 1494.
6. Gruberg L, Mehran R, Dangas G, et al. Acute renal failure requiring dialysis after percutaneous coronary intervention: In-hospital and one-year outcomes. Anaheim, CA: Proceedings of American College of Cardiology; 2000. p 1129-1175.
7. Davidson CJ, Hlatky M, Morris KG, et al. Cardiovascular and renal toxicity of nonionic radiographic contrast agent after cardiac catheterization: A prospective trial. Ann Intern Med 1989;110: 119-124.
8. Parfery PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: A prospective controlled study. N Engl J Med 1989;320:143-149.
9. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial. Kidney Int 1995;47:254-261.
10. Lautin EM, Freeman NJ, Schoenfeld AH, et al. Radiocontrast- associated renal dysfunction: Incidence and risk factors. Am J Roentgenol 1991;157:49-58.
11. Lautin EM, Freeman NJ, Schoenfeld AH, et al. Radiocontrast- associated renal dysfunction: A comparison of lower-osmolality and conventional high-osmolality contrast media. Am J Roentgenol 1991;157:59-65.
12. Taylor AJ, Hotchkiss D, Morse RW. et al. Prepared: A randomized trial of inpatient vs. outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 1998;114:1570-1574.
13. Tepel M, Van Der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced-reduction in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
14. Erley CM, Duda SH, Schlepakow S, et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994;45:1425-1431.
15. Madyoon H, Croushore L, Weaver D, et al. Use of Fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Cathet Cardiovas Intervent 2001;53:341-345.
16. Kini A, Mitre C, Kamran M, et al. Preliminary experience with fenoldopam, a new renal vasodilator, in reducing radiocontrast nephropathy during percutaneous coronary intervention. Am J Cardiol 2000;86(Suppl 8A):1i.
17. Morales PA, Hayes JV, Bailey SR. Contrast-induced nephropathy: Fenoldopam, a new agent to decrease acute renal insufficiency. Am J Cardiol 2000;86(Suppl 8A):1i.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
19. Mathur VS, Swan SK, Lambrecht LJ, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999;27: 1832-1837.
20. Hunter D. Fenoldopam: A dopamine type 1 receptor agonist in the prevention of renal injury associated with the administration of intravascular contrast. J Vasc Intervent Radiol 2000; 11:396 -398.